Download PDF
CC BY-NC-ND 4.0 · J Lab Physicians 2022; 14(03): 306-311
DOI: 10.1055/s-0042-1742632
Original Article

Role of (1-3)-Β-D-Glucan Test in the Diagnosis of Invasive Fungal Infections among High-Risk Patients in a Tertiary Care Hospital

Tanureet Kaur Sandhar
1   Department of Microbiology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India
,
Deepinder Kaur Chhina
1   Department of Microbiology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India
,
Veenu Gupta
1   Department of Microbiology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India
,
Jyoti Chaudhary
1   Department of Microbiology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Background Invasive fungal infections (IFI) are associated with high mortality. Serum fungal biomarkers offer an advantage over the traditional methods in early diagnosis and better clinical outcomes. The aim of the study was to evaluate the role of (1–3)-β-D-glucan (BDG) assay in the patients suspected of IFI.

Materials and Methods This prospective study was conducted in the Department of Microbiology, Dayanand Medical College and Hospital, Ludhiana, over a period of 1 year. A total of 862 serum samples were received from patients suspected of IFI, for the BDG test (Fungitell, Associates of Cape Cod Inc., USA). The test was performed as per kit protocol. Appropriate samples were processed for KOH fungal smear and fungal culture. Blood culture was done by Bactec (Biomerieux).

Statistical Analysis Results were analyzed using descriptive statistical methods. Sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) were calculated at different cutoffs. In addition, the receiver operating characteristic (ROC) curve using SPSS 21.00 software was calculated and the diagnostic accuracy was shown by the area under the ROC curve (AUC).

Results Among 862 patients, 546 (63.3%) were males. The predominant age group (25.6%) was between 61 and 70 years. The most common risk factor (54.8%) was prolonged intensive care unit stay. Out of the total samples, 455 (52.8%) samples were found positive for BDG. Fungal elements were seen in 48 (10.5%) KOH smears and fungal growth was obtained in 81 (17.8%) cultures. Comparison of BDG assay and culture at different cutoffs yielded AUC—0.823. Sensitivity (100%), specificity (51.3%), accuracy (55.6%), PPV (15.8%), and NPV (100%) were observed at the kit cutoff of 80 pg/mL. Optimum sensitivity and specificity of 79.2% and 70.3%, respectively, were observed at a cutoff of 142.4pg/mL. A significant correlation was observed between BDG positivity and piperacillin–tazobactam use and dialysis. Among BDG positive patients, 38(8.4%) succumbed to death.

Conclusion Detection of BDG helps in the early diagnosis of IFI in critically ill patients. As the assay has a high NPV, a negative test can be used to stop the empirical antifungal drugs. The use of a higher cutoff can be useful to avoid false-positive results.

Keywords

invasive fungal infections - (1–3)-β-D-glucan - fungal culture

Note

The study has been approved by ethics committee of the institute.




Publication History

Article published online:
09 February 2022

© 2022. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Paramythiotou E, Frantzeskaki F, Flevari A, Armaganidis A, Dimopoulos G. Invasive fungal infections in the ICU: how to approach, how to treat. Molecules 2014; 19 (01) 1085-1119
    CrossrefPubMedGoogle Scholar
  • 2 Lamoth F, Akan H, Andes D. et al. Assessment of the role of 1,3-β-d-Glucan testing for the diagnosis of invasive fungal infections in adults. Clin Infect Dis 2021; 72 (Suppl. 02) S102-S108
    CrossrefPubMedGoogle Scholar
  • 3 Hou TY, Wang SH, Liang SX, Jiang WX, Luo DD, Huang DH. The screening performance of serum 1,3-beta-D-glucan in patients with invasive fungal diseases: a meta-analysis of prospective cohort studies. PLoS One 2015; 10 (07) e0131602
    CrossrefPubMedGoogle Scholar
  • 4 Xiaoling L, Tingyu T, Caibao H, Tian Z, Changqin C. Diagnostic efficacy of serum 1,3-β-D-glucan for invasive fungal infection: an update meta-analysis based on 37 case or cohort studies. Open Med (Wars) 2018; 13: 329-337
    CrossrefPubMedGoogle Scholar
  • 5 Pickering JW, Sant HW, Bowles CA, Roberts WL, Woods GL. Evaluation of a (1->3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005; 43 (12) 5957-5962
    CrossrefPubMedGoogle Scholar
  • 6 Singh S, Kaur H, Choudhary H. et al. Evaluation of biomarkers: galactomannan and 1,3-beta-D-glucan assay for the diagnosis of invasive fungal infections in immunocompromised patients from a tertiary care centre. Indian J Med Microbiol 2018; 36 (04) 557-563
    CrossrefPubMedGoogle Scholar
  • 7 Miyazaki T, Kohno S, Mitsutake K. et al. Plasma (1–>3)-beta-D-glucan and fungal antigenemia in patients with candidemia, aspergillosis, and cryptococcosis. J Clin Microbiol 1995; 33 (12) 3115-3118
    CrossrefPubMedGoogle Scholar
  • 8 Tran T, Beal SG. Application of the 1,3-β-D-glucan (Fungitell) assay in the diagnosis of invasive fungal infections. Arch Pathol Lab Med 2016; 140 (02) 181-185
    CrossrefPubMedGoogle Scholar
  • 9 Liss B, Cornely OA, Hoffmann D, Dimitriou V, Wisplinghoff H. 1,3-β-D-Glucan contamination of common antimicrobials. J Antimicrob Chemother 2016; 71 (04) 913-915
    CrossrefPubMedGoogle Scholar
  • 10 Kato A, Takita T, Furuhashi M, Takahashi T, Maruyama Y, Hishida A. Elevation of blood (1–>3)-beta-D-glucan concentrations in hemodialysis patients. Nephron 2001; 89 (01) 15-19
    CrossrefPubMedGoogle Scholar
  • 11 Alexander BD, Smith PB, Davis RD, Perfect JR, Reller LB. The (1,3)beta-D-glucan test as an aid to early diagnosis of invasive fungal infections following lung transplantation. J Clin Microbiol 2010; 48 (11) 4083-4088
    CrossrefPubMedGoogle Scholar
  • 12 Zhang Z, Zhu R, Luan Z, Ma X. Risk of invasive candidiasis with prolonged duration of ICU stay: a systematic review and meta-analysis. BMJ Open 2020; 10 (07) e036452
    CrossrefPubMedGoogle Scholar
  • 13 Herbrecht R, Bories P, Moulin JC, Ledoux MP, Letscher-Bru V. Risk stratification for invasive aspergillosis in immunocompromised patients. Ann N Y Acad Sci 2012; 1272: 23-30
    CrossrefPubMedGoogle Scholar
  • 14 Bansal N, Gopalakrishnan R, Sethuraman N. et al. Experience with β-d-glucan assay in the management of critically ill patients with high risk of invasive candidiasis: an observational study. Indian J Crit Care Med 2018; 22 (05) 364-368
    CrossrefPubMedGoogle Scholar
  • 15 Chandrasekar P. Diagnostic challenges and recent advances in the early management of invasive fungal infections. Eur J Haematol 2010; 84 (04) 281-290
    CrossrefPubMedGoogle Scholar
  • 16 Cordonnier C, Botterel F, Ben Amor R. et al. Correlation between galactomannan antigen levels in serum and neutrophil counts in haematological patients with invasive aspergillosis. Clin Microbiol Infect 2009; 15 (01) 81-86
    CrossrefPubMedGoogle Scholar
  • 17 Kaur S, Gupta V, Chhina DK, Singh A, Sharma D. Mycological and serological study of invasive Aspergillosis in a tertiary care hospital. J Microbiol Infect Dis 2018; 8: 8-12
    CrossrefGoogle Scholar
  • 18 Kritikos A, Poissy J, Croxatto A, Bochud PY, Pagani JL, Lamoth F. Impact of the beta-glucan test on management of intensive care unit patients at risk for invasive candidiasis. J Clin Microbiol 2020; 58 (06) e01996-e19
    CrossrefPubMedGoogle Scholar
  • 19 Mikulska M, Furfaro E, Del Bono V. et al. Persistence of a positive (1,3)-beta-D-glucan test after clearance of candidemia in hematopoietic stem cell transplant recipients. Clin Vaccine Immunol 2011; 18 (03) 518-519
    CrossrefPubMedGoogle Scholar
  • 20 Persat F, Ranque S, Derouin F, Michel-Nguyen A, Picot S, Sulahian A. Contribution of the (1–>3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2008; 46 (03) 1009-1013
    CrossrefPubMedGoogle Scholar
  • 21 He S, Hang JP, Zhang L, Wang F, Zhang DC, Gong FH. A systematic review and meta-analysis of diagnostic accuracy of serum 1,3-β-D-glucan for invasive fungal infection: focus on cutoff levels. J Microbiol Immunol Infect 2015; 48 (04) 351-361
    CrossrefPubMedGoogle Scholar
  • 22 Jaijakul S, Vazquez JA, Swanson RN, Ostrosky-Zeichner L. (1,3)-β-D-glucan as a prognostic marker of treatment response in invasive candidiasis. Clin Infect Dis 2012; 55 (04) 521-526
    CrossrefPubMedGoogle Scholar
  • 23 Mennink-Kersten MA, Warris A, Verweij PE. 1,3-beta-D-glucan in patients receiving intravenous amoxicillin-clavulanic acid. N Engl J Med 2006; 354 (26) 2834-2835
    CrossrefPubMedGoogle Scholar
  • 24 Leleu G, Aegerter P, Guidet B. Collège des Utilisateurs de Base de Données en Réanimation. Systemic candidiasis in intensive care units: a multicenter, matched-cohort study. J Crit Care 2002; 17 (03) 168-175
    CrossrefPubMedGoogle Scholar
  • 25 Herbrecht R, Caillot D, Cordonnier C. et al. Indications and outcomes of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic stem cell transplantation. J Antimicrob Chemother 2012; 67 (11) 2731-2738
    CrossrefPubMedGoogle Scholar